US FDA fast-tracks Bayer and Algeta's prostate drug Alpharadin
Germany’s Bayer (BAY: DE) said this morning that its investigational compound Alpharadin (radium-223 chloride), licensed from Norwegian cancer drug developer Algeta ASA (OSE: ALGETA) in 2009 under an up to $800 million deal (The Pharma Letter September 3, 2009), has been granted fast track designation by the US Food and Drug Administration for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.
Saying that this is an important milestone for Alpharadin, Kemal Malik, head of global development and member of the Bayer HealthCare executive committee, noted that "prostate cancer is a leading cause of death among men all over the world. There is a significant unmet need for patients suffering from the advanced stages of the disease, especially in patients whose cancer has spread to the bone."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze